ELAB
PMGC Holdings Inc. NASDAQ Listed Nov 21, 2023$1.15
-14.55%
vs $1.34
Mkt Cap $2.2M
52w Low $1.06
0.0% of range
52w High $309.89
50d MA $1.78
200d MA $49.31
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
0.3x
ROE
-98.9%
P/FCF
-0.0x
RSI (14)
41.10
ATR (14)
$0.10
Beta
0.71
50d MA
$1.78
200d MA
$49.31
Avg Volume
3.7M
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
120 Newport Center Drive · Newport Beach, CA 92660 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | — | -0.52 | — | 1.87 | -2.1% | -10.7% | +113.2% | +68.3% | +133.7% | -59.1% | — |
| Nov 14, 2025 | AMC | — | -19.80 | — | 508.80 | -0.6% | -1.7% | -6.1% | +1.6% | -4.0% | -1.0% | — |
| Aug 12, 2025 | AMC | — | -6.44 | — | 648.96 | +2.2% | +2.1% | -5.7% | +3.8% | +2.5% | +0.0% | — |
| May 14, 2025 | AMC | — | -40.60 | — | 837.12 | +1.1% | -3.7% | +3.0% | +2.0% | +2.4% | -3.4% | — |
| Apr 4, 2025 | AMC | — | -99.99 | — | 1438.08 | -7.0% | -4.4% | -12.0% | +10.9% | -19.5% | -4.4% | — |
| Nov 13, 2024 | AMC | — | -1371.66 | — | 11618.88 | +58.3% | +6.1% | -15.6% | +3.6% | -7.0% | +0.5% | — |
| Aug 14, 2024 | AMC | — | -1567.61 | — | 146529.60 | -3.2% | -3.7% | -1.0% | -1.3% | -14.7% | -8.0% | — |
| May 15, 2024 | AMC | — | -1567.61 | — | 296352.00 | +2.4% | +3.2% | +5.4% | -1.5% | +0.0% | -1.5% | — |
| Mar 29, 2024 | AMC | — | -1567.61 | — | — | — | — | — | — | — | — | — |
| Dec 11, 2023 | AMC | — | -0.08 | — | 870240.00 | -12.4% | -6.5% | +3.8% | +1.4% | -0.5% | +6.9% | — |
| Jun 30, 2023 | AMC | — | -22.55 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -19.04 | — | — | — | — | — | — | — | — | — |
No analyst ratings available.
No insider trades available.
8-K · 7.01
! Medium
PMGC Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 1
8-K · 5.03
! Medium
PMGC Holdings Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 8
8-K · 2.01
!!! Very High
PMGC Holdings Inc. -- 8-K 2.01: Acquisition Completed
May 13
8-K · 7.01
! Medium
PMGC Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
NorthStrike Biosciences, a wholly owned subsidiary of PMGC Holdings (ELAB), disclosed material information on April 28, 2026, through Regulation FD, signaling potential strategic developments requiring investor attention.
Apr 28
8-K · 7.01
! Medium
PMGC Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
NorthStrive Defense Tech LLC, PMGC Holdings' wholly owned subsidiary, disclosed material information on April 23, 2026, potentially signaling strategic updates or operational developments relevant to investors evaluating ELAB's business trajectory.
Apr 23
8-K · 7.01
! Medium
PMGC Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
PMGC Holdings' wholly-owned subsidiary SVM Machining disclosed information on April 21, 2026, though specific details appear incomplete in this filing summary for investor evaluation.
Apr 21
8-K · 1.01
! Medium
PMGC Holdings Inc. -- 8-K 1.01: Equity Issuance
ELAB entered into an equity issuance agreement with an investor, potentially diluting existing shareholders while raising capital for operations or strategic initiatives.
Apr 17
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ELAB secured a long-term aerospace & defense contract ensuring predictable multi-year revenue, reducing business uncertainty and potentially improving valuation multiples for a small-cap supplier.
Apr 9
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ELAB has fully drawn its $20M equity financing facility, providing capital for acquisitions across aerospace, defense, and semiconductor sectors, signaling management confidence in near-term M&A opportunities and reducing near-term dilution risk.
Apr 8
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ELAB secured exclusive drone technology rights in aerospace/defense, potentially expanding its market addressable market and competitive positioning, justifying higher valuation multiples if commercialization succeeds.
Apr 6
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ELAB's formation of NorthStrive Defense Tech subsidiary positions the company to capitalize on high-growth defense and autonomous systems markets, potentially unlocking significant revenue streams and justifying higher valuations if execution succeeds.
Apr 2
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ELAB's subsidiary AGA Precision secured a long-term aerospace supply contract with Turbo-Jet Products, providing revenue visibility and strengthening its position in mission-critical defense manufacturing, likely boosting investor confidence.
Mar 31
8-K · 1.01
!! High
Unknown — 8-K 1.01: License Agreement
ELAB secured a licensing deal with MOA Life Plus, potentially expanding its product pipeline or revenue streams through intellectual property monetization or commercialization rights.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ELAB's ITAR registration enables participation in lucrative U.S. defense contracts, a significant revenue diversification opportunity that investors should monitor for material contract wins and margin expansion.
Mar 24
8-K
Unknown — 8-K Filing
ELAB entered into an amendment on March 17, 2026, suggesting potential changes to existing agreements that could affect financial obligations, partnerships, or operational terms—investors should review the full amendment text to assess materiality and impact.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ELAB announced a stock split on March 4, 2026, which typically increases share accessibility for retail investors and may improve liquidity, though it doesn't change fundamental company value.
Mar 10
8-K · 1.01
!! High
PMGC Holdings Inc. -- 8-K 1.01: Material Agreement
ELAB completed its fourth secured pre-paid equity purchase under an existing facility with an investor, providing additional capital through an arrangement established in September 2025.
Mar 3
8-K · 7.01
! Medium
PMGC Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
I need more complete information from the summary to provide an accurate analysis. The summary appears to be truncated at "The information furnished pursuant to this." Could you provide the full summary of what disclosure ELAB (PMGC Holdings/Elabotech) made under Regulation FD?
Feb 19
8-K · 7.01
! Medium
PMGC Holdings Inc. -- 8-K 7.01: Regulation FD Disclosure
I cannot provide an analysis because the summary is incomplete and doesn't contain sufficient information about the disclosure content, deal terms, or substantive details needed to assess investor impact.
Feb 11
8-K · 1.01
!! High
PMGC Holdings Inc. -- 8-K 1.01: License Agreement
Elab (PMGC Holdings) secured a license agreement with Modulant Biosciences, potentially expanding its bioscience capabilities and revenue opportunities through new intellectual property or technology access.
Feb 10
8-K · 2.01
!!! Very High
PMGC Holdings Inc. -- 8-K 2.01: Acquisition Completed
ELAB completed its acquisition on February 2, 2026, for $2.25 million, expanding its portfolio through this strategic purchase.
Feb 6
Institutional (13F) — Top 2
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ifp Advisors, Inc | 2,000 | $12K | New | Mar 2026 |
| 2 | Ubs Group Ag | 1,302 | $8K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$2.2M
Enterprise Value
-$4.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.00x
P/S
0.02x
P/FCF
-0.00x
EV/EBITDA
—
Shares Out
20K
Financials (TTM)
Revenue
$1.3M
Net Income
-$11.1M
EBITDA
-$9.0M
Free Cash Flow
-$6.4M
Op Cash Flow
-$5.9M
EPS Basic
$-378.74
EPS Diluted
$-218.85
EPS Forward
—
Gross Margin
12.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$12.9M
Total Liab.
$5.0M
Total Equity
$7.8M
Cash
$5.4M
LT Debt
$1.1M
Book Value/Sh
$385.09
Debt/Equity
0.34x
Current Ratio
1.74
Quick Ratio
1.72
Returns & Growth
ROE
-98.9%
ROA
-60.2%
ROIC
-70.2%
Rev Growth YoY
-76.1%
EPS Growth YoY
+94.2%
Price Returns
2W
-3.6%
1M
-13.0%
3M
-61.2%
6M
-96.2%
12M
-99.8%
Technicals
52W High
$309.89
52W Low
$1.06
50d MA
$1.78
200d MA
$49.31
RSI (14)
41.10
ATR (14)
$0.10
Beta
0.71
Avg Volume
3.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 6:49am
· Source: financialmodelingprep.com